Tuesday, August 27, 2013

Sangamo BioSciences Acquires Ceregene

Richmond-based Sangamo BioSciences announced Monday that it is acquiring Ceregene, a biotechnology firm developing adeno-associated virus (AAV) gene therapies. Sangamo said it will issue 100,000 shars of its common stock, plus provide unspecified earnout in the deal. The stock portion of the deal is worth approximately $1.0M, based on Sangamo's recent trading price. Ceregene had been backed by Alta Partners, California Technology Ventures, Cell Genesys, Hamilton BioVentures, Investor Growth Capital Ltd., and MPM Capital, and had raised over $71M in venture funding.